Scarica l'app Stockscreener
2.84
0.35%
0.010
Dopo l'orario di chiusura:
2.84
Precedente Chiudi:
$2.83
Aprire:
$2.83
Volume 24 ore:
47,765
Relative Volume:
0.27
Capitalizzazione di mercato:
$100.75M
Reddito:
-
Utile/perdita netta:
$-27.66M
Rapporto P/E:
-2.9895
EPS:
-0.95
Flusso di cassa netto:
$-24.36M
1 W Prestazione:
-3.40%
1M Prestazione:
+15.92%
6M Prestazione:
+17.84%
1 anno Prestazione:
+66.08%
Intervallo 1D:
$2.83
$2.90
Intervallo di 1 settimana:
$2.83
$3.17
Portata 52W:
$1.60
$5.885
Genelux Corp Stock (GNLX) Company Profile
Nome
Genelux Corp
Settore
Industria
Telefono
805-267-9889
Indirizzo
2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE
Confronta GNLX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GNLX
Genelux Corp
|
2.84 | 100.75M | 0 | -27.66M | -24.36M | -0.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Genelux Corp Stock (GNLX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-10-29 | Iniziato | Guggenheim | Buy |
| 2024-08-28 | Iniziato | ROTH MKM | Buy |
| 2023-11-27 | Iniziato | H.C. Wainwright | Buy |
| 2023-09-12 | Iniziato | Maxim Group | Buy |
| 2023-02-15 | Iniziato | The Benchmark Company | Speculative Buy |
Genelux Corp Borsa (GNLX) Ultime notizie
Genelux (NASDAQ:GNLX) Raised to “Hold” at Wall Street Zen - Defense World
Two Sigma Investments LP Sells 18,446 Shares of Genelux Co. (NASDAQ:GNLX) - Defense World
Citadel Advisors LLC Lowers Position in Genelux Co. (NASDAQ:GNLX) - Defense World
Millennium Management LLC Cuts Stake in Genelux Co. (NASDAQ:GNLX) - Defense World
Wall Street Zen Downgrades Genelux (NASDAQ:GNLX) to Sell - Defense World
Genelux Co. (NASDAQ:GNLX) Given Average Recommendation of “Buy” by Brokerages - Defense World
Genelux (NASDAQ:GNLX) Trading Up 3.3% – Time to Buy? - Defense World
Genelux Corporation (GNLX) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Top Executives at Genelux Corp. Unload Thousands of Shares! - TipRanks
GENELUX Corp Executives Sell Shares to Cover Taxes - TradingView
Genelux Q3 EPS Raised by Brookline Capital Management - Defense World
HC Wainwright Issues Optimistic Outlook for Genelux Earnings - Defense World
Genelux Corp.’s Promising Prospects: Buy Rating Backed by Strong Phase 3 Trial and Financial Position - TipRanks
Genelux (GNLX) Price Target Lowered by Benchmark Analyst | GNLX Stock News - GuruFocus
Promising Developments in Genelux Corp.’s Olvi-Vec Drive Buy Rating - TipRanks
H.C. Wainwright lifts Genelux stock target to $31, maintains buy By Investing.com - Investing.com Nigeria
H.C. Wainwright lifts Genelux stock target to $31, maintains buy - Investing.com
Genelux reports Q1 EPS (21c), consensus (24c) - TipRanks
Genelux (GNLX) Shows Strong Progress in Cancer Treatment Trials | GNLX Stock News - GuruFocus
Genelux Reports 71% Disease Control Rate in Lung Cancer Trial, Q1 2025 Earnings | GNLX Stock News - Stock Titan
Genelux Corporation Reports First Quarter 2025 Financial Results and Provides General Business Updates - Yahoo Finance
Geode Capital Management LLC Has $716,000 Position in Genelux Co. (NASDAQ:GNLX) - Defense World
Genelux CEO Discusses Next-Gen Immuno-Oncology Pipeline and Key Milestones at Citizens Conference - Stock Titan
LPL Financial LLC Has $222,000 Stock Position in Genelux Co. (NASDAQ:GNLX) - Defense World
Is EUROFINS SCIENT (ERFSF) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Raymond James Financial Inc. Takes $41,000 Position in Genelux Co. (NASDAQ:GNLX) - Defense World
Benchmark maintains $25 target on Genelux stock, optimistic on trials - Investing.com
Benchmark maintains $25 target on Genelux stock, optimistic on trials By Investing.com - Investing.com India
HC Wainwright Has Bearish Estimate for Genelux Q1 Earnings - The AM Reporter
Guggenheim Sticks to Their Buy Rating for Genelux Corp. (GNLX) - The Globe and Mail
Analysts Offer Predictions for Genelux Q1 Earnings - Defense World
What is HC Wainwright’s Forecast for Genelux Q1 Earnings? - Defense World
Genelux (NASDAQ:GNLX) Given Buy Rating at HC Wainwright - Defense World
Genelux Corp. Buy Rating: Strategic Financial Positioning and Growth Prospects Amid Clinical Advancements - TipRanks
H.C. Wainwright maintains Buy on Genelux shares, target at $30 By Investing.com - Investing.com South Africa
H.C. Wainwright maintains Buy on Genelux shares, target at $30 - Investing.com
Genelux Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Brokers Set Expectations for Genelux FY2024 Earnings - Defense World
Research Analysts Set Expectations for Genelux Q1 Earnings - The AM Reporter
Genelux reports FY24 EPS (95c), consensus (88c) - TipRanks
FDA Green Light: Genelux's Cancer Drug Olvi-Vec Advances as 2024 Data Shows 71% Disease Control - Stock Titan
GENELUX Corp SEC 10-K Report - TradingView
Down -29.7% in 4 Weeks, Here's Why Genelux Corporation (GNLX) Looks Ripe for a Turnaround - Yahoo Finance
Genelux (GNLX) Projected to Post Quarterly Earnings on Friday - Defense World
Promising Clinical Trial Results and Strong Financial Position Justify Buy Rating for Genelux Corp. - TipRanks
What is HC Wainwright’s Estimate for Genelux Q1 Earnings? - Defense World
Benchmark maintains $25 target on Genelux following trial data - Investing.com
Genelux’s (GNLX) Buy Rating Reaffirmed at HC Wainwright - Defense World
Genelux stock holds Buy rating, $30 target from H.C. Wainwright - Investing.com India
Genelux prices 3M shares at $3.50 in underwritten public offering - TipRanks
Genelux, Newsoara announce preliminary Phase 1b/2 data of Olvi-Vec - TipRanks
Genelux Corp Azioni (GNLX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Genelux Corp Azioni (GNLX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Zindrick Thomas | President and CEO |
May 12 '25 |
Sale |
2.92 |
10,764 |
31,431 |
191,447 |
| Yu Yong | VP, Clinical Trial Operations |
May 12 '25 |
Sale |
2.92 |
5,579 |
16,291 |
47,640 |
| Cappello Joseph | VP, Pharmaceutical Development |
May 12 '25 |
Sale |
2.92 |
4,737 |
13,832 |
52,266 |
| Smalling Ralph | Head of Regulatory |
May 12 '25 |
Sale |
2.92 |
1,259 |
3,676 |
34,760 |
| Tyree James L | Director |
Dec 30 '24 |
Sale |
2.46 |
3,460 |
8,512 |
45,791 |
1.45%
0.86%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):